OBSOLETE: Blepharophimosis-epicanthus inversus-ptosis due to copy number variations

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

1 event
Nov 2021

Cytalux: FDA approved

As an adjunct for intraoperative identification of malignant lesions in adult patients with ovarian cancer

FDAcompleted

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

1 program

FINANCIAL LANDSCAPE SUMMARY

1

Total programs

1

Open now

Patient Assistance Programs1

Cytalux

On Target Laboratories, LLC

OpenContact for details

View all support programs on disease page →

Clinical Trial Landscape

No active clinical trials currently recruiting for OBSOLETE: Blepharophimosis-epicanthus inversus-ptosis due to copy number variations.
Search all trials →
Search clinical trials for OBSOLETE: Blepharophimosis-epicanthus inversus-ptosis due to copy number variations

Recent News & Research

No recent news articles indexed yet for OBSOLETE: Blepharophimosis-epicanthus inversus-ptosis due to copy number variations.
Search PubMed for OBSOLETE: Blepharophimosis-epicanthus inversus-ptosis due to copy number variations

Browse all OBSOLETE: Blepharophimosis-epicanthus inversus-ptosis due to copy number variations news →

Specialist Network

No specialists currently listed for OBSOLETE: Blepharophimosis-epicanthus inversus-ptosis due to copy number variations.

View all OBSOLETE: Blepharophimosis-epicanthus inversus-ptosis due to copy number variations specialists →

Quick Actions